Arovella Therapeutics, a biotechnology company specialising in its invariant Natural Killer T cell therapy platform, appointed Tim Luscombe as CFO effective immediately.

Luscombe, currently a director at Bio101 Financial Advisory, brings over 10 years of finance and commercial experience in both public and private companies within the healthcare sector.

Luscombe replaces Phillip Hains, who served as CFO since July 2020.